These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24305418)

  • 1. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
    Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
    Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
    Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
    Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
    Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
    Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
    Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
    Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
    Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
    Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG
    Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.
    Rong Y; Ning Y; Zhu J; Feng P; Zhu W; Zhao X; Xiong Z; Ruan C; Jin J; Wang H; Cai T; Zhang S; Yang Y
    Mol Biomed; 2024 Sep; 5(1):39. PubMed ID: 39306655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
    Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
    Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
    Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
    Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
    J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L.
    Liu GY; Li ZJ; Li QL; Jin Y; Zhu YH; Wang YH; Liu MY; Li YG; Li Y
    Int Immunopharmacol; 2015 Sep; 28(1):487-93. PubMed ID: 26208317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.